EDIT vs HOLX · rev $32.3M vs P/E 32, rev $4.10B
Editas Medicine Inc (EDIT) versus Hologic Inc (HOLX) — a side-by-side from cached financials, not a winner call.
Editas Medicine Inc (EDIT) is a biotechnology company listed on NASDAQ.
Hologic Inc (HOLX) is a medical instruments & supplies company listed on NASDAQ.
Latest reported EDIT revenue for 2024-12-31 was $32.3M. Net income was -$237.1M. Revenue was down 58.6% from 2023-12-31 to 2024-12-31. EDIT currently screens at market cap $375.2M.
Latest reported HOLX revenue for 2025-09-27 was $4.10B. Net income was $565.7M. Revenue was up 1.7% from 2024-09-28 to 2025-09-27. HOLX currently screens at market cap $16.97B and trailing P/E 31.5.
EDIT currently screens at market cap $375.2M. HOLX currently screens at market cap $16.97B and trailing P/E 31.5.
Not investment advice. Open the EDIT and HOLX stock pages for the full models.
Not investment advice.